Shilpa Medicare's Telangana facility passes TGA, Australia GMP inspection

Shilpa Medicare Ltd has achieved yet another milestone in its pharmaceutical journey as its Unit IV facility, located in Jadcherla, Telangana, successfully completed a Good Manufacturing Practice (GMP) Inspection conducted by TGA, Australia. The positive communication regarding this inspection was received on October 17, 2023.

Unit IV in Telangana is a vital manufacturing hub for Shilpa Medicare, engaged in the production, packaging, labeling, testing, and release of finished dosage forms, which include sterile injections and non-sterile oral solids. These medicines play a crucial role in the treatment of various forms of cancer and adjuvant therapy.

Remarkably, this marks the fourth major regulatory inspection that the site has passed within the past two years, following successful outcomes with regulatory authorities in Russia, Canada, and Brazil. The favorable outcome of the TGA inspection now positions the company to register and market its pharmaceutical products in Australia and other global markets that recognize Australian GMP standards.

This achievement underscores Shilpa Medicare's unwavering commitment to maintaining GMP status and quality standards in alignment with the expectations and norms of global regulatory authorities. The company continues to strive for excellence in the pharmaceutical industry, ensuring the highest quality and standards for its products.